Skip to content

Ayurvedic Management of Covid 19 patients

Ayurvedic Management of asymptomatic & mild symptomatic covid 19 patients - A clinical and laboratory assesment - AMC19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027786
Enrollment
60
Registered
2020-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ayurveda Intervension Bharangyadi kashayam,Sudharshanavati,Guduchi paaneeyam,Thaleesadi choornam for 21 days: 1.Bharangyadi kashayam Dose- 50ml with warm water before food 2.Sudharsha

Sponsors

Principal Secretary Health and Family welfar Govt of Tamilnadu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -COVID-19 positive as determined by RT-PCR or other approved commercial or public health assay -Informed consent for the study -Asymptomatic stage -mild stage (cough, fever) -Respiratory rate saturation > 94%

Exclusion criteria

Exclusion criteria: -Participation in any other clinical trial of an experimental treatment for COVID-19 -Patients with severe COVID-19 disease defined as follows respiratory distress,oxygen saturation at rest complications. Pregnant women or women who are breastfeeding -Immunocompromised patients taking (presently on immunosuppressant medication any time during last 90 days) -Diabetics with >9% HbA1c -Patients on antimicrobials, antibiotics, antifungals during last 30 days -Patients with active malignancy -patients with bleeding disorders -Pandu (Hb

Design outcomes

Primary

MeasureTime frame
To prevent covid19 postive cases in asymptomatic and mild stages progressing into moderate and severe stages assessed by clinical and laboratory parameters and to find the time taken to convert SARSâ??CoVâ??2 negative determined by RT-PCR.Timepoint: Participants will be provided with study medication orally for 21 days, with close follow-up on weekly basis. -Baseline -7th day -14th day -21st day

Secondary

MeasureTime frame
No of cases Reporting any ADR/AE assessed clinically and by laboratory parameters(CBC,CRP,LFT,urea,creatinine)Timepoint: -Baseline -7th day -14th day -21st day

Countries

India

Contacts

Public ContactDr Sunil Roy R

Government Ayurveda Medical College and Hospital,Kottar

drrajumd@gmail.com9751497841

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026